Eric Coldwell
Stock Analyst at Baird
(3.70)
# 739
Out of 5,182 analysts
166
Total ratings
60.38%
Success rate
3.18%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Outperform | $19 → $16 | $9.39 | +70.48% | 10 | Feb 27, 2026 | |
| LH Labcorp Holdings | Maintains: Outperform | $313 → $326 | $273.26 | +19.30% | 15 | Feb 18, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $45.69 | +5.06% | 1 | Jan 12, 2026 | |
| MCK McKesson | Maintains: Outperform | $873 → $927 | $873.43 | +6.13% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $175.55 | +13.36% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $168.98 | +52.68% | 19 | Oct 29, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $106.72 | +109.90% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $197.82 | -1.93% | 11 | Aug 25, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $215.80 | -5.93% | 13 | Aug 13, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $501.50 | -2.29% | 19 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $12.22 | +30.93% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $63.68 | -29.33% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $78.84 | -16.29% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $0.76 | +5,952.63% | 4 | Nov 10, 2017 |
Fortrea Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $19 → $16
Current: $9.39
Upside: +70.48%
Labcorp Holdings
Feb 18, 2026
Maintains: Outperform
Price Target: $313 → $326
Current: $273.26
Upside: +19.30%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $45.69
Upside: +5.06%
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $873.43
Upside: +6.13%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $175.55
Upside: +13.36%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $168.98
Upside: +52.68%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $106.72
Upside: +109.90%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $197.82
Upside: -1.93%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $215.80
Upside: -5.93%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $501.50
Upside: -2.29%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $12.22
Upside: +30.93%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $63.68
Upside: -29.33%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $78.84
Upside: -16.29%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $0.76
Upside: +5,952.63%